150 related articles for article (PubMed ID: 29207057)
1. Molecular mechanism and targeted therapy of Hsp90 involved in lung cancer: New discoveries and developments (Review).
Rong B; Yang S
Int J Oncol; 2018 Feb; 52(2):321-336. PubMed ID: 29207057
[TBL] [Abstract][Full Text] [Related]
2. Nuclear Accumulation of Heat-shock Protein 90 Is Associated with Poor Survival and Metastasis in Patients with Non-small Cell Lung Cancer.
Su JM; Hsu YY; Lin P; Chang H
Anticancer Res; 2016 May; 36(5):2197-203. PubMed ID: 27127123
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
Zismanov V; Drucker L; Gottfried M
Anticancer Drugs; 2014 Oct; 25(9):998-1006. PubMed ID: 25153785
[TBL] [Abstract][Full Text] [Related]
4. 3-O-(Z)-coumaroyloleanolic acid overcomes Cks1b-induced chemoresistance in lung cancer by inhibiting Hsp90 and MEK pathways.
Wang H; Sun M; Guo J; Ma L; Jiang H; Gu L; Wen H; Liao S; Chen J; Zeng B; Li Y; Li Y; Yu X; Feng Y; Zhou Y
Biochem Pharmacol; 2017 Jul; 135():35-49. PubMed ID: 28288818
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
Siegelin MD
Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257
[TBL] [Abstract][Full Text] [Related]
6. The network interaction of the human cytosolic 90 kDa heat shock protein Hsp90: A target for cancer therapeutics.
da Silva VC; Ramos CH
J Proteomics; 2012 Jun; 75(10):2790-802. PubMed ID: 22236519
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of heat shock protein 90 isoforms in small cell lung cancer.
Lee JH; Kang KW; Kim JE; Hwang SW; Park JH; Kim SH; Ji JH; Kim TG; Nam HY; Roh MS; Lee EH; Park MI; Kim MS; Lee HW
Int J Clin Exp Pathol; 2015; 8(8):9487-93. PubMed ID: 26464709
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients.
Biaoxue R; Xiling J; Shuanying Y; Wei Z; Xiguang C; Jinsui W; Min Z
J Exp Clin Cancer Res; 2012 Aug; 31(1):70. PubMed ID: 22929401
[TBL] [Abstract][Full Text] [Related]
9. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
Solárová Z; Mojžiš J; Solár P
Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
[TBL] [Abstract][Full Text] [Related]
10. 17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy.
Karkoulis PK; Stravopodis DJ; Voutsinas GE
Tumour Biol; 2016 May; 37(5):6861-73. PubMed ID: 26662567
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of MSH2 expression by Hsp90 inhibition enhances cytotoxicity affected by tamoxifen in human lung cancer cells.
Ko JC; Chiu HC; Syu JJ; Chen CY; Jian YT; Huang YJ; Wo TY; Jian YJ; Chang PY; Wang TJ; Lin YW
Biochem Biophys Res Commun; 2015 Jan; 456(1):506-12. PubMed ID: 25490383
[TBL] [Abstract][Full Text] [Related]
12. Heat shock proteins and cancer: How can nanomedicine be harnessed?
Sauvage F; Messaoudi S; Fattal E; Barratt G; Vergnaud-Gauduchon J
J Control Release; 2017 Feb; 248():133-143. PubMed ID: 28088573
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells.
Tung CL; Jian YJ; Syu JJ; Wang TJ; Chang PY; Chen CY; Jian YT; Lin YW
Exp Cell Res; 2015 May; 334(1):126-35. PubMed ID: 25662161
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of heat shock proteins 90 and 70 leads to simultaneous degradation of the oncogenic signaling proteins involved in muscle invasive bladder cancer.
Cavanaugh A; Juengst B; Sheridan K; Danella JF; Williams H
Oncotarget; 2015 Nov; 6(37):39821-38. PubMed ID: 26556859
[TBL] [Abstract][Full Text] [Related]
15. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis.
Tsutsumi S; Neckers L
Cancer Sci; 2007 Oct; 98(10):1536-9. PubMed ID: 17645779
[TBL] [Abstract][Full Text] [Related]
16. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
17. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer.
Rodina A; Vilenchik M; Moulick K; Aguirre J; Kim J; Chiang A; Litz J; Clement CC; Kang Y; She Y; Wu N; Felts S; Wipf P; Massague J; Jiang X; Brodsky JL; Krystal GW; Chiosis G
Nat Chem Biol; 2007 Aug; 3(8):498-507. PubMed ID: 17603540
[TBL] [Abstract][Full Text] [Related]
18. Identification of epipolythiodioxopiperazines HDN-1 and chaetocin as novel inhibitor of heat shock protein 90.
Song X; Zhao Z; Qi X; Tang S; Wang Q; Zhu T; Gu Q; Liu M; Li J
Oncotarget; 2015 Mar; 6(7):5263-74. PubMed ID: 25742791
[TBL] [Abstract][Full Text] [Related]
19. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
[TBL] [Abstract][Full Text] [Related]
20. Co-overexpression of Hsp90-β and annexin A1 with a significantly positive correlation contributes to the diagnosis of lung cancer.
Biaoxue R; Shuanying Y; Wei L; Zongjuan M; Xiguang C; Qiuhong Z
Expert Rev Mol Diagn; 2014 Nov; 14(8):1067-79. PubMed ID: 25300907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
